The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days ...
Drug development in oncology is historically challenging, exhibiting a very high attrition rate, with low rates of approval for novel treatments when compared to other therapeutic areas. At present, ...